Consensus Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.95 ^USD	-0.76%		+11.43%	+13.23%

May. 01	Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	CI
Mar. 28	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Cocrystal Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a6ef5579a9005ba.bkqiHL3XTNhKo_LlOqiEJGKUVhUGTeA3aLp-VITx2nM.OXPNafGcer4dlKSyXp3IUT3EYXRjGLBVMMMzJui0sjkiKctU7bkDlB6Otw~0856bf787f4b07c4a5dfde3bd488f417

Analyst Recommendations on Cocrystal Pharma, Inc.

HC Wainwright Adjusts Cocrystal Pharma's Price Target to $12 From $35, Keeps Buy Rating	23-05-24	MT
HC Wainwright Adjusts Price Target on Cocrystal Pharma to $35 From $42, Maintains Buy Rating	23-01-24	MT
HC Wainwright Adjusts Price Target on Cocrystal Pharma to $42 From $48, Maintains Buy Rating	22-11-07	MT
COCRYSTAL PHARMA : HC Wainwright Adjusts Cocrystal Pharma PT to $4 From $4.50, Maintains Buy Rating	21-06-15	MT
COCRYSTAL PHARMA : HC Wainwright Adjusts Cocrystal Pharma Price Target to $4.50 From $5, Maintains Buy Rating	20-11-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.95 USD

Average target price

8.667 USD

Spread / Average Target

+344.44%

High Price Target

10 USD

Spread / Highest target

+412.82%

Low Price Target

6 USD

Spread / Lowest Target

+207.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cocrystal Pharma, Inc.

HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar